Startups BioPharma, CinRx Pharma Corrals $73M to Continue ‘Hub and Spoke’ Model of Startup Formation By Frank Vinluan
BioPharma, Pharma Gearing Up to Challenge Pfizer in a Rare Disease, BridgeBio Secures Up to $1.25B By Frank Vinluan
BioPharma, Pharma BMS builds on BridgeBio alliance, inking deal for rights to KRAS cancer drug By Frank Vinluan
BioPharma, Pharma Heart drug’s trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data By Frank Vinluan
BioPharma, Pharma Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model By Frank Vinluan
BioPharma, Pharma Centessa Pharma’s IPO brings in $330M for its new model of drug R&D By Frank Vinluan
BioPharma BridgeBio turns Alexion asset into first approved drug for rare metabolic disease By Frank Vinluan
BioPharma Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug By Frank Vinluan
BioPharma, Pharma Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases By Frank Vinluan
BioPharma, Pharma FDA Rejection Is a Delay, Not a Detour for Alnylam’s Aim to Treat Heart Disorder By Frank Vinluan
BioPharma, Pharma Star Therapeutics Lands $90M to Expand Its Drug Discovery Universe By Frank Vinluan
BioPharma, Pharma Immunology & Inflammation Biotech Apogee Plans IPO to Demo Dosing Edge in Eczema By Frank Vinluan
